ERBB2 and neoplasm: (102) highlighted the need of deeper insight into the mechanisms on which the interaction between HR-positive/HER2-negative BC tumor and immune cells relies, as various factors such as menopausal status, estrogen levels, and endocrine treatments may be involved in the modulation of the tumor microenvironment (102).